BT Investment Management Ltd purchased a new stake in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 12,508 shares of the company’s stock, valued at approximately $597,000.
A number of other institutional investors and hedge funds have also modified their holdings of PCRX. Teachers Advisors LLC lifted its stake in Pacira Pharmaceuticals by 6.2% in the fourth quarter. Teachers Advisors LLC now owns 62,854 shares of the company’s stock valued at $2,030,000 after buying an additional 3,658 shares during the period. Nationwide Fund Advisors lifted its stake in Pacira Pharmaceuticals by 147.4% in the first quarter. Nationwide Fund Advisors now owns 56,190 shares of the company’s stock valued at $2,562,000 after buying an additional 33,482 shares during the period. US Bancorp DE lifted its stake in Pacira Pharmaceuticals by 50.5% in the first quarter. US Bancorp DE now owns 8,989 shares of the company’s stock valued at $410,000 after buying an additional 3,015 shares during the period. Bank of New York Mellon Corp lifted its stake in Pacira Pharmaceuticals by 4.2% in the first quarter. Bank of New York Mellon Corp now owns 206,435 shares of the company’s stock valued at $9,415,000 after buying an additional 8,366 shares during the period. Finally, Swiss National Bank lifted its stake in Pacira Pharmaceuticals by 2.5% in the first quarter. Swiss National Bank now owns 61,300 shares of the company’s stock valued at $2,795,000 after buying an additional 1,500 shares during the period.
COPYRIGHT VIOLATION NOTICE: “BT Investment Management Ltd Purchases Shares of 12,508 Pacira Pharmaceuticals, Inc. (PCRX)” was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.chaffeybreeze.com/2017/09/21/bt-investment-management-ltd-purchases-shares-of-12508-pacira-pharmaceuticals-inc-pcrx.html.
Pacira Pharmaceuticals, Inc. (NASDAQ PCRX) opened at 35.90 on Thursday. The firm has a 50-day moving average price of $36.91 and a 200-day moving average price of $44.24. The company’s market cap is $1.45 billion. Pacira Pharmaceuticals, Inc. has a 52 week low of $29.95 and a 52 week high of $58.95.
Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its quarterly earnings data on Wednesday, August 2nd. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.06). The company had revenue of $70.90 million for the quarter, compared to analysts’ expectations of $73.37 million. Pacira Pharmaceuticals had a negative net margin of 23.36% and a negative return on equity of 12.44%. The firm’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.21 EPS. Equities research analysts anticipate that Pacira Pharmaceuticals, Inc. will post ($0.17) EPS for the current fiscal year.
Several brokerages have issued reports on PCRX. BMO Capital Markets dropped their price target on Pacira Pharmaceuticals from $42.00 to $40.00 and set a “market perform” rating on the stock in a research note on Thursday, August 3rd. Wedbush reissued an “outperform” rating and issued a $87.00 price target on shares of Pacira Pharmaceuticals in a research note on Wednesday, June 21st. Canaccord Genuity reissued a “buy” rating and issued a $56.00 price target on shares of Pacira Pharmaceuticals in a research note on Monday, July 31st. HC Wainwright set a $59.00 price target on Pacira Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 3rd. Finally, ValuEngine lowered Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $52.92.
In other Pacira Pharmaceuticals news, Director Paul J. Hastings sold 1,044 shares of Pacira Pharmaceuticals stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $36.15, for a total transaction of $37,740.60. Following the completion of the transaction, the director now owns 3,518 shares in the company, valued at $127,175.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Kristen Marie Williams sold 3,461 shares of Pacira Pharmaceuticals stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $36.75, for a total value of $127,191.75. Following the transaction, the chief accounting officer now owns 21,312 shares of the company’s stock, valued at approximately $783,216. The disclosure for this sale can be found here. Insiders have sold 33,390 shares of company stock valued at $1,215,480 in the last quarter. 6.60% of the stock is owned by company insiders.
Pacira Pharmaceuticals Company Profile
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX).
Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.